QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials

Sanofi and QuantHealth team up to advance AI-powered digital twins and clinical trial simulations to accelerate drug development

Tel Aviv & Cambridge, MA – October 1st, 2025 — <u>QuantHealth</u>, a pioneer in Al-driven clinical trial simulation, announced a strategic investment from <u>Sanofi Ventures</u>, the venture capital arm of global healthcare leader Sanofi. The investment will accelerate QuantHealth's efforts to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development, bringing its total funds raised to \$30 million.

QuantHealth's platform enables pharmaceutical companies to virtually simulate clinical trials using real-world data and advanced AI models. By generating millions of patient-level digital twins, the platform predicts trial outcomes and optimizes protocol design, aiming to improve trial success rates, timelines, and cost efficiency.

The investment has further catalyzed an enterprise strategic relationship that supports Sanofi's focus on integrating advanced AI and digital technologies to drive transformation across its R&D ecosystem. As part of the investment, Cris De Luca, Partner at Sanofi Ventures, will join as an observer on QuantHealth's Board of Directors.

"We're proud to welcome Sanofi Ventures as an investor and strategic ally in our journey," said Orr Inbar, CEO and Co-founder of QuantHealth. "Sanofi is at the forefront of digital transformation in pharma, and this relationship will help us scale our impact and bring more predictive, AI-driven approaches to clinical development."

"QuantHealth has the potential to transform how clinical trials are designed and optimized," said Cris De Luca, Partner at Sanofi Ventures. "Their approach to leveraging digital twins and real-world data is advancing the next generation of R&D, and I look forward to supporting the team."

"At Sanofi, we are building an AI-first organization, and engaging with innovators like QuantHealth is central to our strategy," said Emmanuel Frenehard, Chief Digital Officer at Sanofi. "Their platform represents an important opportunity to reimagine clinical trial design through simulation, and we're excited to explore this capability together."

This investment and enterprise relationship underscores a shared commitment to advancing drug development through the responsible use of artificial intelligence in life sciences.

###

About QuantHealth

QuantHealth is an AI-driven clinical trial simulation company that helps pharmaceutical companies design faster, more successful trials using real-world data and predictive modeling. With access to over 350 million patient records and proprietary AI algorithms, QuantHealth's platform simulates trials at scale to optimize protocols, reduce risk, and accelerate timelines.

About Sanofi Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi, investing globally in early-stage biotech

and digital health companies aligned with Sanofi's mission to chase the miracles of science. Areas of focus include immunology, oncology, rare diseases, vaccines, and digital innovation.